HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial Por Ning Li, Shu Zhang, Yan Song, Jing Huang, Qun Li, Xinjun Liang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou

Obter o texto integral